HC Wainwright Has Optimistic Outlook of ALNY Q3 Earnings

Key Points

• HC Wainwright has significantly raised its Q3 2025 EPS estimate for Alnylam Pharmaceuticals from a loss of $0.64 to a gain of $0.40, reaffirming a "Buy" rating with a price target of $570.00.
• Alnylam recently reported $0.32 EPS for the previous quarter, outperforming expectations by $0.86 and saw revenue increase by 17.3% year-over-year to $773.69 million.
• Insider trading saw notable sales, with CEO Yvonne Greenstreet selling shares worth over $3 million, indicating a decrease in their stake by 11.04%.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) - Research analysts at HC Wainwright raised their Q3 2025 earnings estimates for shares of Alnylam Pharmaceuticals in a research note issued on Tuesday, September 2nd. HC Wainwright analyst P. Trucchio now forecasts that the biopharmaceutical company will post earnings per share of $0.40 for the quarter, up from their prior forecast of ($0.64). HC Wainwright has a "Buy" rating and a $570.00 price target on the stock. The consensus estimate for Alnylam Pharmaceuticals' current full-year earnings is ($1.70) per share. HC Wainwright also issued estimates for Alnylam Pharmaceuticals' Q4 2025 earnings at $1.38 EPS, FY2025 earnings at $0.84 EPS, FY2026 earnings at $17.37 EPS, FY2027 earnings at $32.51 EPS and FY2028 earnings at $34.46 EPS.

ALNY has been the subject of several other reports. Bank of America lifted their target price on shares of Alnylam Pharmaceuticals from $336.00 to $359.00 and gave the stock a "buy" rating in a report on Friday, July 11th. Piper Sandler lifted their target price on shares of Alnylam Pharmaceuticals from $304.00 to $449.00 and gave the stock an "overweight" rating in a report on Friday, August 1st. Morgan Stanley boosted their price objective on shares of Alnylam Pharmaceuticals from $312.00 to $405.00 and gave the company an "equal weight" rating in a report on Friday, August 1st. Chardan Capital boosted their price objective on shares of Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the company a "buy" rating in a report on Friday, August 1st. Finally, Wall Street Zen cut shares of Alnylam Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Friday. Twenty-two investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $417.38.

Alnylam Pharmaceuticals Stock Down 0.3%

NASDAQ:ALNY traded down $1.54 during mid-day trading on Friday, hitting $452.00. 751,495 shares of the company's stock were exchanged, compared to its average volume of 1,057,829. Alnylam Pharmaceuticals has a one year low of $205.87 and a one year high of $469.81. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75. The business has a fifty day moving average price of $387.47 and a 200 day moving average price of $310.11. The company has a market cap of $59.25 billion, a PE ratio of -183.00 and a beta of 0.32.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, topping analysts' consensus estimates of ($0.54) by $0.86. The company had revenue of $773.69 million during the quarter, compared to analyst estimates of $633.54 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. Alnylam Pharmaceuticals's revenue for the quarter was up 17.3% on a year-over-year basis. During the same period in the prior year, the business posted ($0.13) earnings per share. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. grew its position in Alnylam Pharmaceuticals by 1.8% during the 2nd quarter. Vanguard Group Inc. now owns 13,297,139 shares of the biopharmaceutical company's stock worth $4,336,064,000 after purchasing an additional 240,534 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its stake in shares of Alnylam Pharmaceuticals by 0.8% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 4,418,145 shares of the biopharmaceutical company's stock valued at $1,192,988,000 after purchasing an additional 33,696 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in shares of Alnylam Pharmaceuticals by 5.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,505,168 shares of the biopharmaceutical company's stock valued at $946,466,000 after purchasing an additional 185,783 shares during the period. Geode Capital Management LLC lifted its stake in shares of Alnylam Pharmaceuticals by 3.3% in the 2nd quarter. Geode Capital Management LLC now owns 2,398,770 shares of the biopharmaceutical company's stock valued at $779,857,000 after purchasing an additional 75,936 shares during the period. Finally, Orbis Allan Gray Ltd lifted its stake in shares of Alnylam Pharmaceuticals by 29.8% in the 2nd quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company's stock valued at $691,771,000 after purchasing an additional 486,489 shares during the period. Hedge funds and other institutional investors own 92.97% of the company's stock.

Insider Buying and Selling

In related news, Director Michael W. Bonney sold 11,250 shares of Alnylam Pharmaceuticals stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $450.00, for a total transaction of $5,062,500.00. Following the completion of the sale, the director owned 16,804 shares in the company, valued at $7,561,800. This trade represents a 40.10% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Jeffrey V. Poulton sold 2,274 shares of the business's stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $453.27, for a total transaction of $1,030,735.98. Following the completion of the sale, the executive vice president owned 50,121 shares of the company's stock, valued at approximately $22,718,345.67. This represents a 4.34% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 57,594 shares of company stock worth $25,551,456 over the last three months. 1.20% of the stock is currently owned by company insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.